Back to results

Safety, Tolerability, and Pharmacokinetics of Orally Inhaled DNAzyme Solution for Nebulisation in Healthy Male Subjects

Primary Purpose

Asthma

Status

Completed

Phase

Phase 1

Locations

Germany

Study Type

Interventional

Intervention

SB010

Placebo

About this trial

This is an interventional treatment trial for Asthma focused on measuring Antisense oligonucleotide, Asthma, Healthy subjects, Phase 1, Transcription factor GATA-3, Oral inhalation

Eligibility Criteria

18 Years - 45 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

Written consent to participation in the trial prior to trial start and any trial-related procedure.
Healthy male Caucasian subject - healthy based on a screening examination including medical history, without clinically relevant pathologies, physical examination, vital signs, ECG assessment, pulmonary function testing, and clinical laboratory results.
Body weight according to a body mass index (BMI) between 18 and 29 kg/m2 (inclusive); body weight between 60 and 90 kg.
Non-smokers or ex-smokers (stopped smoking for at least 5 years prior to start of the clinical study).
Ability to inhale in an appropriate manner.

Exclusion Criteria:

History or current evidence of clinically relevant allergies or idiosyncrasy to any drug or food.
History of allergic reactions to any active or inactive component of the study medication.
History or current evidence of any clinically relevant pulmonary, cardiovascular, hepatic, renal, gastrointestinal, haematological, endocrinological, metabolic, neurological, or psychiatric disease within the last 2 years.
ECG abnormalities of clinical relevance (e.g., QTc according to Bazett's ³440 ms, PR ³210 ms; or QRS ³120 ms).
Subjects with a resting heart rate <50 bpm, systolic blood pressure <100 mmHg, diastolic blood pressure <60 mmHg.
Proneness to orthostatic dysregulation, fainting, or blackouts.
History or presence of any malignancy except for basalioma.
Abnormalities in clinical chemical or haematologic variables considered medically relevant by the investigator.
Chronic or acute infections.
Positive results in any of the following virology tests: human immunodeficiency virus (HIV) antibodies and antigen, Anti-hepatitis B-core antibody, hepatitis B surface antigen (HBsAg) and anti-hepatitis C virus antibody.
Positive drug screen.
History of previous administration of any registered or investigational oligonucleotide-based drug.
History or presence of alcohol or drug abuse.
Treatment with any known enzyme inducing or inhibiting agents (e.g., St. John's Wort (Johanniskraut), barbiturates, phenothiazines, cimetidine, ketoconazole, etc.) within 30 days before administration of IMP or during the trial.
Use of any medication (including over-the-counter medication, herbal products) except allowed concomitant medication within 2 weeks (for biologics: 6 months) before administration of IMP or within <10 times the elimination half-life of the respective drug, or the duration of the pharmacodynamic effect, whatever is longer.
Consumption of any enzyme inducing or inhibiting aliments and beverages (e.g., broccoli, Brussels sprout, grapefruit, grapefruit juice, star fruit etc.) within 14 days prior to the IMP administration or during the trial.
Consumption of any caffeine- or theophylline-containing product 48 h before administration of IMP.
Consumption of alcohol within 48 h before administration of IMP.
Vegetarian diet or other dietary habits, which would preclude the subject's acceptance of standardised meals.
Surgery of the gastrointestinal tract except for appendectomy or herniotomy.
Planned donation of germ cells, blood, organs, bone marrow during the course of the trial or within 6 months thereafter.
Participation in another clinical trial with an investigational drug or device within the last 3 months. For biologics, the minimum exclusion period is at least 6 months or the time of duration of the pharmacodynamic effect or 10 times the half-life of the respective drug whatever is longer before inclusion in this trial.
Blood donation within the last 30 days before screening.
Lack of ability or willingness to give informed consent.
Anticipated non-availability for trial visits/procedures.
Anticipated lack of willingness or inability to cooperate adequately.
Vulnerable subjects (e.g., persons kept in detention).

Sites / Locations

CRS Clinical Research Services Mannheim GmbH

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

SB010

Placebo

Arm Description

The drug SB010 is administered in phosphate-buffered saline solution, inhaled via a controlled breathing system over a 5 to 10 min.

The placebo (phosphate-buffered saline) is administered as a solution inhaled via a controlled breathing system over a 5 to 10 min.

Outcomes

Primary Outcome Measures

Limiting dose of inhaled ascending single dose of SB010.

Safety will be monitored as adverse events, vital signs, clinical chemistry, haematology, urinalysis, electrocardiogram, pulmonary function testing, body temperature, overall tolerability.

Secondary Outcome Measures

Number of participants with any dose-limiting adverse effects.

Safety will be monitored as adverse events, vital signs, clinical chemistry, haematology, urinalysis, electrocardiogram, pulmonary function testing, body temperature, overall tolerability.

Maximum tolerated dose.

Safety will be monitored as adverse events, vital signs, clinical chemistry, haematology, urinalysis, electrocardiogram, pulmonary function testing, body temperature, overall tolerability.

Single-dose plasma concentration of hgd40 over time after inhalation of SB010.

The following pharmacokinetic parameters will be determined in plasma samples over 4 days: Area under the plasma concentration-time curve; Concentration maximum; Time of maximum concentration; Apparent terminal elimination half-life; Area under the concentration-time curve until the last sampling time;

Feasibility of the inhalative technique.

Study participants will be instructed on the correct inhalation technique. Ability to breath in through the mouth and exhale through the nose will be assessed during the inhalation procedure. Forced Expiratory Volume in 1 second(FEV1*) will be monitored at screening and throughout the study after the single dose of the study drug: Days 1, 2, 3, 4, 12±2, and 60±4 *FEV1 = the maximal amount of air forcefully exhaled in one second

Full Information

NCT ID

NCT01470911

First Posted

October 31, 2011

Last Updated

November 21, 2012

Sponsor

Sterna Biologicals GmbH & Co. KG

1. Study Identification

Unique Protocol Identification Number

NCT01470911

Brief Title

Safety, Tolerability, and Pharmacokinetics of Orally Inhaled DNAzyme Solution for Nebulisation in Healthy Male Subjects

Official Title

Phase-I Study in Healthy Male Subjects to Investigate Safety, Tolerability and Pharmacokinetics of Orally Inhaled Single Doses of SB010, a Human GATA-3-specific DNAzyme Solution for Nebulisation.

Study Type

Interventional

2. Study Status

Record Verification Date

November 2012

Overall Recruitment Status

Completed

Study Start Date

November 2011 (undefined)

Primary Completion Date

December 2011 (Actual)

Study Completion Date

December 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Sterna Biologicals GmbH & Co. KG

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

Asthma is a chronic inflammatory bronchial disorder with three distinct components: airway hyper-responsiveness (respiratory hypersensitivity), airway inflammation, and intermittent airway obstruction. One of the characteristics of the disease is an inflammatory reaction of the immune system caused by cytokine production. A substantial number of asthma patients do not satisfactorily respond to steroid therapy and consequently have an unmet medical need for novel targeted therapies with improved specificity, tolerability, and compliance. Novel therapeutic strategies for the treatment of chronic inflammatory diseases by targeting early disease-causing mechanisms are a promising approach for the treatment of asthma. The transcription factor GATA-3 plays a key role in mediating the asthmatic immune response and has been shown to be necessary and sufficient for the production of cytokines interleukin (IL)-4, IL-5, and IL-13. The active principle hgd40 of the investigational medicinal product SB010 belongs to a new class of antisense oligonucleotide therapeutics, the 10-23 DNA (deoxyribonucleic acid) zymes (antisense oligonucleotide). DNAzymes are catalytically active nucleic acids that cleave complementary RNA (ribonucleic acid) molecules. By cleaving GATA-3 mRNA hgd40 reduces specific cytokine production and thereby reduces key features of allergic airway inflammation. DNAzymes are completely generated by chemical synthesis and can be produced under Good Manufacturing Practice (GMP) controlled conditions. The DNAzymes are not biological drugs, i.e. they are not generated by use of any living organism including cell culture or bacteria. The molecules are highly water-soluble and will be applied as solution directly in their synthesized form. The current study will evaluate the safety and tolerability of increasing single doses of inhaled SB010 in healthy male subjects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Asthma

Keywords

Antisense oligonucleotide, Asthma, Healthy subjects, Phase 1, Transcription factor GATA-3, Oral inhalation

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 1

Interventional Study Model

Parallel Assignment

Masking

ParticipantInvestigatorOutcomes Assessor

Allocation

Randomized

Enrollment

46 (Actual)

8. Arms, Groups, and Interventions

Arm Title

SB010

Arm Type

Experimental

Arm Description

The drug SB010 is administered in phosphate-buffered saline solution, inhaled via a controlled breathing system over a 5 to 10 min.

Arm Title

Placebo

Arm Type

Placebo Comparator

Arm Description

The placebo (phosphate-buffered saline) is administered as a solution inhaled via a controlled breathing system over a 5 to 10 min.

Intervention Type

Drug

Intervention Name(s)

SB010

Intervention Description

Six ascending dose groups (DG) are planned, with a total of 48 subjects. DG 1 and 2 will consist of n=6 subjects (n=3 receiving SB010, n=3 placebo). The following DG will consist of n=9 subjects (n=6 receiving SB010, n=3 placebo). The number of subjects to be exposed to active compound will be limited on a particular study day. Subjects of a particular DG will be divided into subgroups and exposed to the drug on different days. In DG 1 and 2, the time interval between the two administrations of the first subgroup will be at least 2 hours. In DG 3-6, the time interval between two subsequent administrations will be at least 1 hour. Dose level (DL) 1: 0.4 mg hgd40/2 mL; DL 2: 2 mg hgd40/2 mL; DL 3: 5 mg hgd40/2 mL; DL 4: 10 mg hgd40/2 mL; DL 5: 20 mg hgd40/2 mL; DL 6: 40 mg hgd40/2 mL.

Intervention Type

Drug

Intervention Name(s)

Placebo

Intervention Description

Primary Outcome Measure Information:

Title

Limiting dose of inhaled ascending single dose of SB010.

Description

Safety will be monitored as adverse events, vital signs, clinical chemistry, haematology, urinalysis, electrocardiogram, pulmonary function testing, body temperature, overall tolerability.

Time Frame

Study period 4 days, follow up visit 12±2 days, end of study day 60±4 days; maximum of 78 days for a particular subject.

Secondary Outcome Measure Information:

Title

Number of participants with any dose-limiting adverse effects.

Description

Safety will be monitored as adverse events, vital signs, clinical chemistry, haematology, urinalysis, electrocardiogram, pulmonary function testing, body temperature, overall tolerability.

Time Frame

Study period 4 days, follow up visit 12±2 days, end of study day 60±4 days; maximum of 78 days for a particular subject.

Title

Maximum tolerated dose.

Description

Safety will be monitored as adverse events, vital signs, clinical chemistry, haematology, urinalysis, electrocardiogram, pulmonary function testing, body temperature, overall tolerability.

Time Frame

Study period 4 days, follow up visit 12±2 days, end of study day 60±4 days; maximum of 78 days for a particular subject.

Title

Single-dose plasma concentration of hgd40 over time after inhalation of SB010.

Description

Time Frame

Day 1 to 4 of the study.

Title

Feasibility of the inhalative technique.

Description

Time Frame

Day 1.

10. Eligibility

Sex

Male

Minimum Age & Unit of Time

18 Years

Maximum Age & Unit of Time

45 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Written consent to participation in the trial prior to trial start and any trial-related procedure. Healthy male Caucasian subject - healthy based on a screening examination including medical history, without clinically relevant pathologies, physical examination, vital signs, ECG assessment, pulmonary function testing, and clinical laboratory results. Body weight according to a body mass index (BMI) between 18 and 29 kg/m2 (inclusive); body weight between 60 and 90 kg. Non-smokers or ex-smokers (stopped smoking for at least 5 years prior to start of the clinical study). Ability to inhale in an appropriate manner. Exclusion Criteria: History or current evidence of clinically relevant allergies or idiosyncrasy to any drug or food. History of allergic reactions to any active or inactive component of the study medication. History or current evidence of any clinically relevant pulmonary, cardiovascular, hepatic, renal, gastrointestinal, haematological, endocrinological, metabolic, neurological, or psychiatric disease within the last 2 years. ECG abnormalities of clinical relevance (e.g., QTc according to Bazett's ³440 ms, PR ³210 ms; or QRS ³120 ms). Subjects with a resting heart rate <50 bpm, systolic blood pressure <100 mmHg, diastolic blood pressure <60 mmHg. Proneness to orthostatic dysregulation, fainting, or blackouts. History or presence of any malignancy except for basalioma. Abnormalities in clinical chemical or haematologic variables considered medically relevant by the investigator. Chronic or acute infections. Positive results in any of the following virology tests: human immunodeficiency virus (HIV) antibodies and antigen, Anti-hepatitis B-core antibody, hepatitis B surface antigen (HBsAg) and anti-hepatitis C virus antibody. Positive drug screen. History of previous administration of any registered or investigational oligonucleotide-based drug. History or presence of alcohol or drug abuse. Treatment with any known enzyme inducing or inhibiting agents (e.g., St. John's Wort (Johanniskraut), barbiturates, phenothiazines, cimetidine, ketoconazole, etc.) within 30 days before administration of IMP or during the trial. Use of any medication (including over-the-counter medication, herbal products) except allowed concomitant medication within 2 weeks (for biologics: 6 months) before administration of IMP or within <10 times the elimination half-life of the respective drug, or the duration of the pharmacodynamic effect, whatever is longer. Consumption of any enzyme inducing or inhibiting aliments and beverages (e.g., broccoli, Brussels sprout, grapefruit, grapefruit juice, star fruit etc.) within 14 days prior to the IMP administration or during the trial. Consumption of any caffeine- or theophylline-containing product 48 h before administration of IMP. Consumption of alcohol within 48 h before administration of IMP. Vegetarian diet or other dietary habits, which would preclude the subject's acceptance of standardised meals. Surgery of the gastrointestinal tract except for appendectomy or herniotomy. Planned donation of germ cells, blood, organs, bone marrow during the course of the trial or within 6 months thereafter. Participation in another clinical trial with an investigational drug or device within the last 3 months. For biologics, the minimum exclusion period is at least 6 months or the time of duration of the pharmacodynamic effect or 10 times the half-life of the respective drug whatever is longer before inclusion in this trial. Blood donation within the last 30 days before screening. Lack of ability or willingness to give informed consent. Anticipated non-availability for trial visits/procedures. Anticipated lack of willingness or inability to cooperate adequately. Vulnerable subjects (e.g., persons kept in detention).

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Wolfgang Timmer, MD

Organizational Affiliation

CRS-Mannheim GmbH, Germany

Official's Role

Principal Investigator

Facility Information:

Facility Name

CRS Clinical Research Services Mannheim GmbH

City

Mannheim

ZIP/Postal Code

68167

Country

Germany

12. IPD Sharing Statement

Learn more about this trial

Safety, Tolerability, and Pharmacokinetics of Orally Inhaled DNAzyme Solution for Nebulisation in Healthy Male Subjects

We'll reach out to this number within 24 hrs